Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Most acute injuries show significant resolution
In the obese trial cohort, 1 mg moved 24-hour ambulatory heart rate by +0.7 bpm at week 24 the peak of the heart-rate curve, and below the placebo arms +0.8. In a healthy lean Phase 1 group, the same dose raised heart rate by about 10 bpm, with a peak near 15 to 20 bpm around days 4 to 6. Lean, younger participants had more reactive heart-rate control than the sedentary, obese, and metabolically stressed trial population
Research Use Only AHK-Cu has not been evaluated by the FDA for safety or efficacy in humans
Choose whichever site is most comfortable and convenient for you, and rotate between both for optimal long-term tissue health
